DK4122923T3 - Oxadiazolderivat - Google Patents
OxadiazolderivatInfo
- Publication number
- DK4122923T3 DK4122923T3 DK21770862.7T DK21770862T DK4122923T3 DK 4122923 T3 DK4122923 T3 DK 4122923T3 DK 21770862 T DK21770862 T DK 21770862T DK 4122923 T3 DK4122923 T3 DK 4122923T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxadiazole derivative
- oxadiazole
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046138 | 2020-03-17 | ||
| PCT/JP2021/010628 WO2021187486A1 (ja) | 2020-03-17 | 2021-03-16 | オキサジアゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4122923T3 true DK4122923T3 (da) | 2025-12-15 |
Family
ID=77768228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21770862.7T DK4122923T3 (da) | 2020-03-17 | 2021-03-16 | Oxadiazolderivat |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12624011B2 (en) * | 2020-03-17 | 2026-05-12 | Sumitomo Pharma Co., Ltd. | Oxadiazole derivative |
| JP7653399B2 (ja) | 2021-09-22 | 2025-03-28 | 住友ファーマ株式会社 | オキサジアゾール誘導体を含有する医薬組成物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1227978A (cg-RX-API-DMAC7.html) * | 1968-09-13 | 1971-04-15 | ||
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| RU2426731C2 (ru) * | 2005-12-23 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | Производные арил-изоксазоло-4-ил-оксадиазола |
| RU2009127095A (ru) * | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| GB0723814D0 (en) * | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| JP5746612B2 (ja) * | 2008-03-19 | 2015-07-08 | オーリムメッド・ファルマ・インコーポレーテッド | 中枢神経系疾患および障害の治療に有効な新規化合物 |
| WO2010017132A1 (en) * | 2008-08-04 | 2010-02-11 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US20110224304A1 (en) * | 2008-11-14 | 2011-09-15 | Dainippon Sumitomo Pharma Co., Ltd. | Biphenylacetamide derivative |
| JP2012001537A (ja) * | 2010-05-19 | 2012-01-05 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体からなる医薬 |
| WO2011145669A1 (ja) * | 2010-05-19 | 2011-11-24 | 大日本住友製薬株式会社 | アミド誘導体 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| SI2772482T1 (sl) * | 2011-10-27 | 2016-06-30 | Taisho Pharmaceutical Co., Ltd. | Derivat azola |
| JP2013221025A (ja) * | 2012-04-19 | 2013-10-28 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体の製造方法及びその中間体 |
| WO2014072957A1 (en) * | 2012-11-12 | 2014-05-15 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
| WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| TW201729807A (zh) * | 2015-10-30 | 2017-09-01 | Ptc治療公司 | 用於治療癲癇的方法 |
| US12624011B2 (en) * | 2020-03-17 | 2026-05-12 | Sumitomo Pharma Co., Ltd. | Oxadiazole derivative |
-
2021
- 2021-03-16 US US17/905,847 patent/US12624011B2/en active Active
- 2021-03-16 CN CN202180036916.0A patent/CN115515943B/zh active Active
- 2021-03-16 ES ES21770862T patent/ES3041051T3/es active Active
- 2021-03-16 JP JP2022508381A patent/JP7637121B2/ja active Active
- 2021-03-16 MX MX2022011483A patent/MX2022011483A/es unknown
- 2021-03-16 WO PCT/JP2021/010628 patent/WO2021187486A1/ja not_active Ceased
- 2021-03-16 AU AU2021239631A patent/AU2021239631B2/en active Active
- 2021-03-16 PT PT217708627T patent/PT4122923T/pt unknown
- 2021-03-16 BR BR112022017530A patent/BR112022017530A2/pt unknown
- 2021-03-16 EP EP21770862.7A patent/EP4122923B1/en active Active
- 2021-03-16 CA CA3170273A patent/CA3170273A1/en active Pending
- 2021-03-16 TW TW110109295A patent/TWI879917B/zh active
- 2021-03-16 KR KR1020227035750A patent/KR20220154208A/ko active Pending
- 2021-03-16 PH PH1/2022/552373A patent/PH12022552373A1/en unknown
- 2021-03-16 FI FIEP21770862.7T patent/FI4122923T3/fi active
- 2021-03-16 DK DK21770862.7T patent/DK4122923T3/da active
-
2022
- 2022-09-16 US US17/932,871 patent/US11718592B2/en active Active
-
2025
- 2025-02-14 JP JP2025022409A patent/JP2025081449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12624011B2 (en) | 2026-05-12 |
| US20230092498A1 (en) | 2023-03-23 |
| US20230265061A1 (en) | 2023-08-24 |
| TWI879917B (zh) | 2025-04-11 |
| ES3041051T3 (en) | 2025-11-06 |
| FI4122923T3 (fi) | 2025-11-12 |
| EP4122923A4 (en) | 2024-04-24 |
| KR20220154208A (ko) | 2022-11-21 |
| CA3170273A1 (en) | 2021-09-23 |
| AU2021239631A8 (en) | 2022-12-01 |
| TW202146392A (zh) | 2021-12-16 |
| JP2025081449A (ja) | 2025-05-27 |
| WO2021187486A1 (ja) | 2021-09-23 |
| CN115515943B (zh) | 2024-07-09 |
| PH12022552373A1 (en) | 2023-12-18 |
| AU2021239631B2 (en) | 2026-05-14 |
| PT4122923T (pt) | 2025-12-03 |
| JP7637121B2 (ja) | 2025-02-27 |
| BR112022017530A2 (pt) | 2022-10-18 |
| EP4122923B1 (en) | 2025-09-10 |
| CN115515943A (zh) | 2022-12-23 |
| EP4122923A1 (en) | 2023-01-25 |
| JPWO2021187486A1 (cg-RX-API-DMAC7.html) | 2021-09-23 |
| AU2021239631A1 (en) | 2022-11-10 |
| US11718592B2 (en) | 2023-08-08 |
| MX2022011483A (es) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4253377A4 (en) | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| EP4186256C0 (en) | INTER-AGENCY COMMUNICATION VIA AN AD-HOC NETWORK SLICE | |
| EP4137404A4 (en) | Multicopter | |
| EP4272364A4 (en) | TA NTN REPORT | |
| EP4223314A4 (en) | LIPID NANOPARTICLE | |
| EP4222352A4 (en) | BOLTER | |
| EP4107782A4 (en) | MICROARRAYS | |
| EP4744661A2 (en) | NEW PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | |
| EP4208295C0 (de) | Fleischwolf | |
| EP4301748C0 (en) | TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| IL304774A (en) | Enhanced sophorolipid derivatives | |
| EP3957265A4 (en) | MICROSCOPE COVER | |
| EP4063561C0 (en) | REFINER SEGMENT | |
| EP4204218C0 (en) | TAPE LAYING HEAD | |
| EP4163277C0 (en) | NEW PYRAZOLE DERIVATIVES | |
| DK4396183T3 (da) | Substituerede s-alaninatderivater | |
| EP4308572C0 (en) | NEW THIENOPYRIMIDINONE DERIVATIVES | |
| EP4121679C0 (de) | Mehrschlauchanordnung | |
| EP4192823C0 (en) | TRIAZOLES DIFLUOROMETHYL-PYRIDIN-2-YL | |
| PT4122923T (pt) | Derivado de oxadiazole | |
| EP4137402A4 (en) | MULTICOPTER | |
| EP4357336A4 (en) | BENZOXAZINONE DERIVATIVES | |
| EP4308576C0 (en) | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | |
| EP4154884A4 (en) | Anti-sars-cov-2 durg |